Prognostic value of Sox2 expression in digestive tract cancers: A meta-analysis

Abstract

The aim of the present study was to accurately evaluate the association of Sox2 expression with the survival of patients with digestive tract cancers. Relevant literatures were identified by comprehensively searching databases including the Pubmed, Embase, CBMdisc, and Wanfang (up to October 2014). A meta-analysis was performed to clarify the association between Sox2 expression and overall survival or clinicopathological parameters of patients with digestive tract cancers (esophageal, gastric, and colorectal cancers). The results showed a significant association between high Sox2 expression and poor overall survival in patients with digestive tract carcinomas (HR=1.55, 95% CI=1.04-2.31), especially for patients with esophageal cancer (HR=2.04, 95%CI=1.30-3.22), colorectal cancer (HR=1.40, 95% CI=1.04-1.89), and digestive tract adenocarcinoma (HR=1.80, 95% CI=1.12-2.89), for Europeans (HR=1.98, 95% CI=1.44-2.71) or patients who did not receive neoadjuvant treatment (HR=1.73, 95% CI=1.10-2.72). Furthermore, Sox2 over-expression was highly correlated with vascular invasion (OR=1.86, 95% CI=1.25-2.77) and poor differentiation (OR=1.88, 95% CI=1.14-3.08), especially in esophageal and colorectal cancers. In conclusion, Sox2 expression may serve as a novel prognostic factor for patients with digestive tract cancers. Over-expression of Sox2 that is correlated with vascular invasion and poor differentiation suggests poor outcomes of patients with digestive tract cancers.

Clinical and Survival Impact of Sex-Determining Region Y-Box 2 in Colorectal Cancer: An Integrated Analysis of the Immunohistochemical Study and Bioinformatics Analysis

“…e previous meta-analysis only included eight studies with small sample sizes (n � 1113) and only analyzed the correlation between SOX2 and overall survival (OS) and a small part of the clinical features of CRC. Additionally, the result on OS was not reasonable [22]. erefore, the significance of SOX2 expression in CRC is not fully understood.…”

The Clinical and Molecular Characteristics of Sex-Determining Region Y-Box 2 and its Prognostic Value in Breast Cancer: A Systematic Meta-Analysis

“…SOX2 expression is common across a wide range of human tumors, such as gastric, colorectal, lung, and ovarian cancers [16]. Its expression is closely related to worse prognosis in some types of human cancers [17, 18]. SOX2 overexpression is found in cancer metastasis [49].…”

“…CSC marker SOX2 is frequently expressed in many human cancers, such as gastric cancer, colorectal cancer, lung cancer, and ovarian carcinoma [16]. Some studies show that SOX2 expression is associated with poor prognosis in some cancers such as esophageal, colorectal, and head and neck cancers [17, 18]. However, SOX2 expression is correlated with a favorable prognosis in non-small cell lung cancer [19].…”

Predictive Value of Stemness Factor Sox2 in Gastric Cancer Is Associated with Tumor Location and Stage

“…A meta-analysis revealed that Sox2 over-expression was associated neither with the overall survival nor with the other clinicopathological factors with obvious heterogeneity[30–31]. In our study, we analyzed the data, with respect to stratification, based on tumor location and stage, we found that Sox2 had predictive value in cardiac gastric cancers or earlier stage (Stages I and II), but not in non-cardiac gastric cancers or later stage (Stages III and IV).…”